The EFECT™ (Effector Function Enhancement & Control Technology) Platform represents the next-generation of optimized monoclonal antibody constant regions with tailored effector function for specific therapeutic needs. The EFECT™ Platform consists of proprietary engineered IgG1 antibody Fc domains with highly selective and specific binding to various Fcγ receptors. The landscape of FcγR receptors and allotypes targeted by the engineered Fc domains include: CD16a, CD16b, CD32a, CD32b, and CD64.
The EFECT™ platform enables the enhancement or suppression of Antibody Dependent Cellular Cytotoxicity (“ADCC”), which is a critical consideration in designing best-in-class antibody therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Potential benefits from modulating ADCC include improved therapeutic efficacy and lower dosing.